NASDAQ:CERS

Cerus (CERS) Stock Forecast, Price & News

$1.51

-0.06 (-3.82%)

(As of 01:16 PM ET)

Compare

Today's Range: $1.49
▼
$1.57
50-Day Range: $1.50
▼
$3.07
52-Week Range: $1.45
▼
$4.25

Volume: 484,324 shs
Average Volume: 1.35 million shs
Market Capitalization: $273.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.88

Cerus MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 225.0% Upside
$4.88 Price Target
Short Interest: Healthy
2.96% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$12,675 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.22) to ($0.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

417th out of 976 stocks

Surgical & Medical Instruments Industry

52nd out of 99 stocks

3.2

Analyst's Opinion

Consensus Rating
Cerus has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.88, Cerus has a forecasted upside of 225.0% from its current price of $1.50.
Amount of Analyst Coverage
Cerus has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.96% of the outstanding shares of Cerus have been sold short.
Short Interest Ratio / Days to Cover
Cerus has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Cerus has recently decreased by 4.11%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cerus does not currently pay a dividend.
Dividend Growth
Cerus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERS.

3.4

News and Social Media Coverage

News Sentiment
Cerus has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cerus this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerus insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,675.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.05% of the stock of Cerus is held by insiders.
Percentage Held by Institutions
81.72% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cerus are expected to grow in the coming year, from ($0.22) to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerus is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerus is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerus has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cerus (NASDAQ:CERS) Stock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CERS Price History

30 days | 90 days | 365 days | Advanced Chart

CERS Stock News Headlines

September 27, 2023 | finance.yahoo.com

Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

September 12, 2023 | finance.yahoo.com

Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference

October 3, 2023 | Goldco (Ad)

Biden's Digital Dollar Nightmare

On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!

August 11, 2023 | seekingalpha.com

Cerus: Profitability Needs To Come Faster As Cash Is Running Out

August 2, 2023 | sfgate.com

Cerus: Q2 Earnings Snapshot

August 2, 2023 | finance.yahoo.com

Cerus Corporation Announces Second Quarter 2023 Financial Results

August 2, 2023 | finance.yahoo.com

Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates

July 31, 2023 | finance.yahoo.com

Cerus (NASDAQ:CERS) investors are sitting on a loss of 60% if they invested three years ago

October 3, 2023 | Goldco (Ad)

Biden's Digital Dollar Nightmare

July 21, 2023 | nasdaq.com

Cerus Corporation Common Stock (CERS)

July 19, 2023 | finance.yahoo.com

Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023

June 15, 2023 | finance.yahoo.com

Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress

June 14, 2023 | finance.yahoo.com

Cerus Corporation Celebrates World Blood Donor Day 2023

June 5, 2023 | seekingalpha.com

Cerus bags additional $8.7M contract amendment

June 5, 2023 | finance.yahoo.com

Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

May 30, 2023 | finance.yahoo.com

With 72% institutional ownership, Cerus Corporation (NASDAQ:CERS) is a favorite amongst the big guns

May 18, 2023 | msn.com

Cerus Earnings Perspective: Return On Capital Employed

May 4, 2023 | finance.yahoo.com

Cerus Corporation Announces First Quarter 2023 Financial Results

May 4, 2023 | finance.yahoo.com

Cerus (CERS) Reports Q1 Loss, Lags Revenue Estimates

April 20, 2023 | finance.yahoo.com

Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023

April 18, 2023 | finance.yahoo.com

Cerus Corporation (NASDAQ:CERS) Might Not Be As Mispriced As It Looks

March 6, 2023 | markets.businessinsider.com

BTIG Keeps Their Hold Rating on Cerus (CERS)

March 1, 2023 | finance.yahoo.com

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results

February 21, 2023 | finance.yahoo.com

Cerus (NASDAQ:CERS) shareholders have endured a 43% loss from investing in the stock a year ago

February 15, 2023 | finance.yahoo.com

Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

January 9, 2023 | finance.yahoo.com

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update

December 21, 2022 | finance.yahoo.com

Cerus Corporation's (NASDAQ:CERS) recent 9.2% pullback adds to one-year year losses, institutional owners may take drastic measures

See More Headlines

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings: 8/02/2023
Today: 10/03/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:CERS
CUSIP: 15708510
CIK: 1020214
Web: www.cerus.com
Phone: (925) 288-6000
Fax: 925-288-6001
Employees: 665
Year Founded: 1991

Price Target and Rating

Average Stock Price Forecast: $4.88
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $3.75
Forecasted Upside/Downside: +225.0%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,780,000.00
Net Margins: -33.24%
Pretax Margin: -32.99%
Return on Equity: -80.35%
Return on Assets: -24.24%

Debt

Debt-to-Equity Ratio: 1.06
Current Ratio: 2.01
Quick Ratio: 1.47

Sales & Book Value

Annual Sales: $162.05 million
Price / Sales: 1.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.39 per share
Price / Book: 3.85

Miscellaneous

Outstanding Shares: 180,800,000
Free Float: 168,057,000
Market Cap: $271.20 million
Optionable: Optionable
Beta: 1.13

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. William M. Greenman (Age 56)
Pres, CEO & Director
Comp: $1.33M

Mr. Kevin D. Green (Age 51)
VP of Fin. & CFO
Comp: $748.49k

Mr. Vivek K. Jayaraman (Age 48)
Chief Operating Officer
Comp: $861.67k

Ms. Chrystal Jensen (Age 52)
Chief Legal Officer & Gen. Counsel
Comp: $692.16k

Dr. Richard J. Benjamin (Age 63)
Chief Medical Officer
Comp: $719.74k

Dr. Laurence M. Corash (Age 79)
Co-Founder & Chief Scientific Officer

Ms. Lori L. Roll
VP of Admin. & Corp. Sec.

Mr. Matthew M. Notarianni
Sr. Director of Investor Relations

Lainie Corten
VP of Global Marketing

Ms. Carol M. Moore (Age 73)
Sr. VP of Regulatory Affairs, Quality & Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERS Stock - Frequently Asked Questions

Should I buy or sell Cerus stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings or view top-rated stocks.
What is Cerus' stock price forecast for 2023?: 3 analysts have issued 1-year target prices for Cerus' stock. Their CERS share price forecasts range from $3.75 to $6.00. On average, they predict the company's stock price to reach $4.88 in the next year. This suggests a possible upside of 225.0% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.
How have CERS shares performed in 2023?: Cerus' stock was trading at $3.65 on January 1st, 2023. Since then, CERS stock has decreased by 58.9% and is now trading at $1.50.
View the best growth stocks for 2023 here.
When is Cerus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CERS earnings forecast.
How were Cerus' earnings last quarter?: Cerus Co. (NASDAQ:CERS) issued its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The biotechnology company earned $38.85 million during the quarter, compared to the consensus estimate of $40.80 million. Cerus had a negative net margin of 33.24% and a negative trailing twelve-month return on equity of 80.35%.
What ETFs hold Cerus' stock?: ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK).
What guidance has Cerus issued on next quarter's earnings?: Cerus updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $172.56 million.

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?: 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cerus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).
What is Cerus' stock symbol?: Cerus trades on the NASDAQ under the ticker symbol "CERS."
How do I buy shares of Cerus?: Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cerus' stock price today?: One share of CERS stock can currently be purchased for approximately $1.50.
How much money does Cerus make?: Cerus (NASDAQ:CERS) has a market capitalization of $271.20 million and generates $162.05 million in revenue each year. The biotechnology company earns $-42,780,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.
How many employees does Cerus have?: The company employs 665 workers across the globe.
How can I contact Cerus?: Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial